替格瑞洛与氯吡格雷在老年急性冠脉综合征患者中的比较:SWEDEHEART登记研究
主要缺血结局(死亡、心梗或卒中)两组相似(HR 0.97,95%CI 0.88-1.06),但替格瑞洛与更高的死亡(HR 1.17,95%CI 1.03-1.32)和出血(HR 1.48,95%CI 1.25-1.76)风险相关,而心肌梗死(HR 0.80,95%CI 0.70-0.92)和卒中(HR 0.72,95%CI 0.56-0.93)风险更低。
要点
- ≥80岁心梗患者中,替格瑞洛与氯吡格雷主要缺血结局相似。
- 替格瑞洛增加死亡和出血风险,但降低心梗和卒中风险。
- 80岁以下患者中替格瑞洛主要缺血结局更低,提示年龄差异。
核心结论
- 在≥80岁心肌梗死患者中,替格瑞洛与氯吡格雷相比主要缺血结局相似,但死亡和出血风险更高。
研究设计与样本
- 使用逆概率治疗加权Cox回归模型调整人口学、院内治疗和药物差异。
- 主要缺血结局(死亡、心肌梗死或卒中)和出血从国家登记处获取,随访1年。
主要发现
- ≥80岁患者中,替格瑞洛与氯吡格雷主要缺血结局风险相似(HR 0.97,95%CI 0.88-1.06)。
- 替格瑞洛与更高死亡风险(HR 1.17,95%CI 1.03-1.32)和出血风险(HR 1.48,95%CI 1.25-1.76)相关。
- 替格瑞洛与更低心肌梗死风险(HR 0.80,95%CI 0.70-0.92)和卒中风险(HR 0.72,95%CI 0.56-0.93)相关。
- <80岁患者中,替格瑞洛主要缺血结局风险低17%(HR 0.83,95%CI 0.77-0.89),死亡风险低15%(HR 0.85,95%CI 0.76-0.96),出血风险高32%(HR 1.32,95%CI 1.18-1.47),心肌梗死风险低(HR 0.82,95%CI 0.75-0.91),卒中风险低(HR 0.82,95%CI 0.69-0.98)。
临床怎么用
- 对于≥80岁心肌梗死患者,选择替格瑞洛需权衡较高的出血和死亡风险与较低的心梗和卒中风险。
- 需开展随机对照研究验证替格瑞洛与氯吡格雷在老年患者中的疗效与安全性。
局限性
- 本研究为观察性分析,可能存在残余混杂。
- 结论需随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The comparative efficacy and safety of ticagrelor versus clopidogrel in older patients with myocardial infarction (MI) has received limited study. METHODS: We performed an observational analysis of all patients ≥80 years (n=14 005) who were discharged alive with aspirin combined with either clopidogrel (60.2%) or ticagrelor (39.8%) after a MI between 2010 and 2017 registered in the national registry SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). Inverse probability treatment weighting was used in Cox regression models to adjust for differences in demographics, in-hospital therapies, and medications. The primary ischemic outcome (death, MI, or stroke), and bleeding were obtained from national registries at 1 year. A sensitivity analysis in <80-year-old patients was performed. RESULTS: In patients ≥80 years, the incidence of the primary ischemic outcome (hazard ratio [HR], 0.97 [95% CI, 0.88-1.06]) was similar for ticagrelor- and clopidogrel-treated patients. Ticagrelor was associated with a 17% and 48% higher risk of death (HR, 1.17 [95% CI, 1.03-1.32]) and bleeding (HR, 1.48 [95% CI, 1.25-1.76]), but a lower risk of MI (HR, 0.80 [95% CI, 0.70-0.92]) and stroke (HR, 0.72 [95% CI, 0.56-0.93]). In <80-year-old patients, the incidence of the primary ischemic outcome was 17% (HR, 0.83 [95% CI, 0.77-0.89]) lower with ticagrelor. Ticagrelor was associated with 15% (HR, 0.85 [95% CI, 0.76-0.96]) lower risk of death, 32% higher risk of bleeding (HR, 1.32 [95% CI, 1.18-1.47]), but lower risk of MI (HR, 0.82 [95% CI, 0.75-0.91]) and stroke (HR, 0.82 [95% CI, 0.69-0.98]). CONCLUSIONS: Ticagrelor use among elderly patients with MI was associated with higher risk of bleeding and death compared with clopidogrel. A randomized study of ticagrelor versus clopidogrel in the elderly is needed.
引用
- Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Circulation. 2020. PMID: 32867508. doi:10.1161/CIRCULATIONAHA.120.050645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。